BOSTON and JERUSALEM , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan Lieber as its U.S.-based CFO. Mr. Lieber will be responsible for all investor relations, finance and

Enrollment Continues for Phase 2 study for oral PTH in Osteoporosis; Top-line 3-month Biomarker Data expected in mid 2020 Presented Positive Results of a Phase 2 PK/PD study in Hypoparathyroidism patients. Conference call and live webcast today at 8:30 am Eastern Time BOSTON and JERUSALEM, Nov.

Conference Call Scheduled for 8:30am ET / 3:30pm IST BOSTON and JERUSALEM, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), announced today that it will report financial results for the third quarter and nine months ended September 30, 2019 before the U.S.

  Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting   Data suggest favorable pharmacologic and pharmacokinetic profiles of Entera’s Oral PTH formulation with a flexible oral

JERUSALEM, Israel and BOSTON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) announced today that Adam Gridley, CEO, and Dr. Phillip Schwartz, President of R&D, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:00 am Eastern

Phase 2 study for oral PTH in osteoporosis was initiated in June 2019; Data expected in 2020 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Results expected to be presented in Q3 2019. Appointed Adam Gridley as Chief Executive Officer Conference call and live webcast

Conference Call Scheduled for 8:30am ET / 1:30pm BST JERUSALEM , Aug. 15, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it will report financial results for the second quarter and six months ended June 30, 2019 before the U.S.

JERUSALEM, Israel , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today the appointment of Adam Gridley as Chief Executive Officer, effective immediately. Phillip Schwartz , Ph.D., former CEO of Entera since the Company’s inception in 2010, will continue with the

JERUSALEM , July 02, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), announced today that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH (1-34) tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three different

Phase 2b Study for oral PTH in osteoporosis to begin by mid-year 2019 Completed Part 2 of a Phase 2 PK/PD study in hypoparathyroidism patients. Data processing and statistical analysis are ongoing, with results expected to be presented in 2H 2019. Appointed Dana Yaacov-Garbeli, CPA, as interim